Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow KPRX by emailGet an email when KPRX pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about KPRX, unsubscribe in one click. Privacy
📣 What KPRX Says Is Next
late 2026 · “We expect to report initial clinical data in late 2026.”
Company press release, Aug 7, 2026 · SEC filing
first quarter of 2027 · “We expect the last patient, first visit in the first quarter of 2027 with topline data in the third quarter of 2027.”
Company press release, Aug 7, 2026 · SEC filing
late 2028 · ““With our current cash position, expected collaboration reimbursements, and additional capital raised subsequent to quarter end, we believe we have sufficient runway to fund operations into late 2028, beyond our anticipated clinical data readouts, providing flexibility as we continue to execute on our development strategy.” Kiora ended the quarter with $13.9 million in cash and short-term investments.”
Company press release, May 8, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full KPRX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for KPRX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.